The Promise of Olaparib for the Treatment of HER2-Negative Breast Cancer

In an interview with Targeted Oncology, Ben Jones identified the key challenges community oncologists are facing due to legislative changes in cancer care policy.

In season 3, episode 3 of Targeted Talks, William J. Gradishar, MD, discusses the latest version of the NCCN Clinical Practice Guideline for managing early-stage breast cancer.

During a Community Case Forum live event in partnership with The Arizona Clinical Oncology Society, Felipe Batalini, MD, discussed the TROPiCS-02 trial of sacituzumab govitecan and the impact of the UGT1A1 status on adverse event frequency.

In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.

The FDA has approved Lumisight and the Lumicell Direct Visualization System for fluorescence imaging in adult patients with breast cancer.

Aaron Lisberg, MD, discussed the phase 3 TROPION-Lung01 study which evaluated datopotamab deruxtecan for patients with advanced or metastatic non-small cell lung cancer.